IMNM FY 2020 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$755,000

Operating Income

-$12M

Net Income

-$18M

EPS (Diluted)

$-1.69

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$13M

Stock-Based Comp.

$621,000

Balance Sheet

Total Assets

$45M

Total Liabilities

$3M

Stockholders' Equity

$41M

Cash & Equivalents

$40M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$755,000	-$615,000	-22.8%
Operating Income	-$12M	-$10M	-18.5%
Net Income	-$18M	-$11M	-69.1%